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Abstract
Aim: This	 study	examined	 the	 influence	of	different	human	milk	 fortifiers	on	bio‐
markers	of	gastrointestinal	immaturity	and	inflammation	in	preterm	infants.
Methods: We	 report	 secondary	 outcomes	 from	 a	 controlled,	 double‐blind,	 ran‐
domised,	parallel	group	study	conducted	 from	2011	to	2014	 in	neonatal	 intensive	
care	units	at	11	metropolitan	hospitals	in	France,	Belgium,	Germany,	Switzerland	and	
Italy.	Preterm	infants	born	at	up	to	32	weeks	or	weighing	up	to	1500	g	were	ran‐
domised	to	a	new	powdered	human	milk	fortifier	(n	=	77)	or	a	control	fortifier	(n	=	76)	
for	a	minimum	of	21	days.	We	analysed	faecal	markers	of	gut	inflammation,	namely	
alpha‐1	antitrypsin	and	calprotectin,	and	maturity,	namely	elastase‐1.
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1  | INTRODUC TION
Preterm	infants	have	immature	development	at	birth1 and are more 
likely	 to	 need	 specialised	 care	 in	 the	 immediate	postpartum	period	
than	term	infants.	Immaturity	of	the	gastrointestinal	system	is	a	par‐
ticular	concern,	as	it	has	been	associated	with	severe	morbidities,	in‐
cluding	necrotising	enterocolitis	(NEC).2	It	also	influences	the	ability	of	
the	infant	to	digest,	absorb	and	use	the	nutrients	needed	to	support	
further	growth	and	development.3	Gut	immaturity,	and	the	associated	
increased	risk	in	morbidity	and	feeding	intolerance,	makes	the	choice	
of	appropriate	enteral	nutrition	extremely	important.	Although	giving	
a	preterm	infant	human	milk	provides	many	them	with	benefits,4,5	the	
nutritional	profile	of	unfortified	human	milk	is	insufficient	to	meet	the	
increased	demands	for	growth	in	this	population.6	As	a	result,	human	
milk	 fortification	 is	 recommended	 for	all	 infants	born	weighing	 less	
than	1800	g.7	While	feeding	fortified	human	milk	has	been	shown	to	
have	no	adverse	effect	on	feeding	tolerance	in	preterm	infants,8	the	
influence	of	different	human	milk	fortifiers	on	markers	of	gut	maturity	
and	gastrointestinal	inflammation	has	not	been	well	studied.
Maturity	 of	 gastrointestinal	 function	 and	 inflammation	 can	 be	
assessed	using	faecal	biomarkers,	which	provide	a	non‐invasive	and	
early	method	for	detecting	any	increased	risk	for	these	conditions.9 
Alpha‐1	antitrypsin	 is	a	serum	trypsin	 inhibitor	that	 is	highly	resis‐
tant	to	intestinal	proteolysis.	The	extravasation	of	alpha‐1	antitryp‐
sin	into	the	gut	can	be	measured	in	the	stools	and	is	a	classic	marker	
for	protein‐losing	enteropathies	or	conditions	that	result	 in	 loss	of	
blood	 proteins	 into	 the	 intestinal	 tract.10	 This	 process	 happens	 in	
intestinal	 inflammation,	 as	 a	 result	 of	 mucosal	 ulceration	 or	 aug‐
mented	permeability.	The	total	protein	 in	stools	 is	another	marker	
of	protein‐losing	enteropathy	and	gut	 inflammation.	Faecal	calpro‐
tectin	reflects	various	pathological	processes	that	occur	in	the	mu‐
cosa	of	paediatric	patients,	with	elevated	concentrations	indicating	
pathogenesis.11	 Faecal	 elastase‐1	 is	 a	 highly	 specific	 and	 sensitive	
test	for	determining	gut	functional	maturity,	specifically	pancreatic	
exocrine	function,	and	differentiating	severe	from	milder	pancreatic	
insufficiency.12	In	preterm	infants,	these	parameters	can	be	used	as	
non‐invasive	markers	for	pancreatic	function,	intestinal	permeability	
and	intestinal	complications	such	as	NEC.12‐14
The	purpose	of	this	study	was	to	assess	the	effect	of	two	human	
milk	 fortifiers	with	 different	 composition	 on	 faecal	 biomarkers	 of	
gastrointestinal	 inflammation	and	maturity	of	gut	 function	 in	clini‐
cally	stable	preterm	infants.	Faecal	biomarkers	were	the	secondary	
endpoints	of	a	trial	that	evaluated	weight	gain	velocity,	other	growth	
parameters	and	nutritional	biomarkers,	including	lipid	profiles,	in	clin‐
ically	stable	preterm	infants	The	new	fortifier	was	PreNAN	Human	
Milk	Fortifier	(Nestlé,	Vevey,	Switzerland),	and	the	control	fortifier	
was	FM85	Human	Milk	 Fortifier	 (Nestlé,	Vevey,	 Switzerland).	 The	
primary	results	of	the	trial	have	already	been	reported.15,16	Briefly,	
they	showed	that	the	unadjusted	weight	gain	rate	was	18.3	g/kg/d	
for	 the	new	 fortifier	 and	16.8	 g/kg/d	 for	 the	 control	 fortifier	 and	
that	both	fortifiers	were	well	 tolerated,	with	a	similar	 incidence	of	
adverse	gastrointestinal	events.	The	adjusted	mean	weight	gain	was	
2.3	g/d	greater	for	the	new	fortifier	and	the	lower	limit	of	the	95%	
Results: Faecal	alpha‐1	antitrypsin	was	slightly	 lower	in	the	new	than	control	forti‐
fier	group	after	21	days	of	full	enteral	feeding,	with	a	geometric	mean	and	standard	
deviation	of	1.52	±	1.32	vs	1.82	±	1.44	mg/g	stools	(P	=	.01).	There	was	no	significant	
difference	in	faecal	calprotectin	(median	[Q1‐Q3]	of	296	[136‐565]	μg/g	stools	in	both	
groups	combined	at	study	day	21).	Faecal	elastase‐1	was	lower	in	the	new	fortifier	
than	control	fortifier	group	(202.5	±	1.6	vs	257.7	±	1.5	μg/g	stools,	P	=	.016).
Conclusion: Mean	values	for	each	parameter	were	within	the	ranges	in	healthy	term	
infants,	indicating	favourable	markers	of	gastrointestinal	status	in	both	groups.	In	ad‐
dition,	for	faecal	calprotectin,	the	relatively	high	concentration	observed	in	preterm	
infants	fed	fortified	human	milk	suggests	that	the	threshold	level	for	detecting	necro‐
tising	enterocolitis	should	be	revised.
K E Y W O R D S
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Key notes
•	 This	 study	 examined	 the	 influence	of	 different	 human	
milk	fortifiers	on	biomarkers	of	gastrointestinal	immatu‐
rity	and	inflammation	in	preterm	infants.
•	 We	report	secondary	outcomes	from	a	controlled,	dou‐
ble‐blind,	 randomised,	 parallel	 group	 study	 in	 neona‐
tal	 intensive	care	units	at	11	metropolitan	hospitals	 in	
France,	Belgium,	Germany,	Switzerland	and	Italy.
•	 Mean	values	for	each	parameter	were	within	the	ranges	
in	healthy	term	infants,	indicating	favourable	markers	of	
gastrointestinal	status	in	both	groups.
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confidence	interval	of	0.4	g/d	exceeded	both	the	noninferiority	and	
superiority	margins.
2  | METHODS
This	 report	 presents	 secondary	 outcomes	 from	 a	 controlled,	 dou‐
ble‐blind,	 randomised,	 parallel	 group	 study	 that	was	 conducted	 in	
neonatal	intensive	care	units	at	11	metropolitan	hospitals	in	France,	
Belgium,	 Germany,	 Switzerland	 and	 Italy.	 Each	 provided	 between	
25	and	45	beds.	We	included	clinically	stable	preterm	infants	born	
from	April	2011	to	March	2014	at	up	to	32	weeks	of	gestation	or	
with	a	birthweight	of	up	to	1500	g.	The	mothers	agreed	to	provide	
expressed	or	donor	breast	milk	for	the	21‐day	study	duration.	The	
inclusion	and	exclusion	criteria	have	previously	been	reported.15,16
The	fortifiers	were	both	based	on	cows'	milk	and	they	provided	
similar	energy,	namely	17	kcal	per	100	mL	of	human	milk.	For	every	
100	mL	 of	HM,	 the	 new	 human	milk	 formula	 provided	 1.4	 g	 par‐
tially	hydrolysed	whey	protein,	0.7	g	lipids,	1.3	g	carbohydrate	and	
a	blend	of	micronutrients.	The	control	human	milk	fortifier	provided	
1.0	g	extensively	hydrolysed	whey	protein,	no	lipids,	3.3	g	carbohy‐
drate	 and	 a	 blend	of	micronutrients.	 The	new	 fortifier	was	devel‐
oped	with	 a	 higher	 protein	 to	 energy	 ratio,	with	 protein	 provided	
as	partially	hydrolysed	whey	and	non‐protein	energy	from	lipids,	as	
medium‐chain	 triglycerides	and	docosahexaenoic	acid.	 It	also	con‐
tained	higher	electrolyte	and	vitamin	levels,	while	achieving	a	lower	
osmolality.	The	aim	was	to	comply	with	the	recommendation	from	
the	European	Society	 for	Paediatric	Gastroenterology	Hepatology	
and	Nutrition17	and	the	discussions	by	an	expert	group	reported	by	
Koletzko	et	al.18
Infants	 tolerating	 ≥100	mL/kg/d	 of	 human	milk	 for	 >24	 hours	
were	 randomised	 to	 receive	either	 the	new	or	control	 fortifier	 for	
21	days	after	they	had	achieved	full	enteral	feeding.	The	fortifiers	
that	were	given	to	the	infants	started	at	half‐strength,	and	this	was	
called	fortification	strength	(increase)	day	one	(FS	day	one).	 It	was	
then	increased	in	 line	with	hospital	practice,	with	the	full‐strength	
fortification	being	 reached	when	 infants	could	maintain	 intakes	of	
150‐180	mL/kg/d,	 namely	 full	 enteral	 feeds	 and	 full	 fortification.	
This	was	called	study	day	one	and	occurred	approximately	3	days	
after	 fortification	 began.	 The	 measurements	 then	 continued	 for	
another	21	days.	 FS	day	one	occurred	 at	 a	median	 (Q1‐Q3)	of	 13	
(11‐18)	 days	 in	 the	 new	 group	 and	 14	 (10‐20)	 days	 in	 the	 control	
group.	The	mean	days	of	life	for	study	day	one	were	16	(13‐20)	vs	
17	(13‐23)	days,	respectively,	and	36	(33‐40)	vs	37	(33‐43)	for	study	
day 21.
Stool	 samples	 were	 collected	 on	 FS	 day	 one	 or	 the	 day	 after	
and	at	21	±	1	days	 (day	21).	They	were	analysed	for	 the	following	
parameters:	 gastrointestinal	 inflammation,	 namely	 faecal	 alpha‐1	
antitrypsin,	calprotectin	and	total	protein,	and	maturity	of	gut	func‐
tion,	 namely	 faecal	 elastase‐1.	Approximately	 5‐8	 g	was	 collected	
from	 each	 infant	 within	 2	 hours	 of	 a	 bowel	 movement.	 Samples	
were	 stored	 frozen	 at	 −20°C	 and	 shipped	 for	 analysis	 on	 dry	 ice.	
If	the	stool	sample	quantity	was	below	5.5	g,	which	was	judged	to	
be	 insufficient,	 a	 second	 collection	was	made	 from	 a	 later	 bowel	
movement	on	the	same	or	 following	day.	Concentrations	of	 faecal	
calprotectin	and	elastase‐1	were	assessed	by	enzyme‐linked	immu‐
nosorbent	assays,	following	sample	treatment	with	the	Smart	Prep	
faecal	 extraction	 device	 (Roche	 Diagnostics).	 These	 were	 as	 fol‐
lows:	EK‐Cal	 (Bühlmann	Laboratories);	ScheBo	Pancreatic	Elastase	
1	 (ScheBo	Biotech	AG)	 and	Euroimmun	Analyzer	A1	 (Euroimmun).	
Faecal	 alpha‐1	 antitrypsin	 concentration	 was	 assessed	 by	 immu‐
nonephelometry,	 using	 the	 IMMAGE	 800	 (Beckman	 Coulter)	 and	
faecal	 total	 protein	 by	 near‐infrared	 spectroscopy	 with	 the	 Fenir	
8820	(Perten	Instruments).	All	the	analyses	were	completed	in	a	cen‐
tral	laboratory	(Rothen	Medizinische	Laboratorien	AG).
FS	day	one	values	were	log‐transformed	and	groups	were	com‐
pared	using	t	 tests	computed	with	the	Satterthwaite	method.	Day	
21	values	were	log‐transformed	and	analysed	using	analysis	of	cova‐
riance	(ANCOVA),	adjusted	for	the	FS	day	one	value	of	the	relevant	
parameter,	sex	and	centre	(random	effect).	Changes	from	FS	day	one	
to	day	21	were	analysed	using	ANCOVA,	adjusted	for	postmenstrual	
age	and	weight	at	study	day	one,	when	full	enteral	feeding	and	full	
fortification	had	been	achieved,	the	FS	day	one	value	of	the	relevant	
parameter,	sex	and	centre	(random	effect).	As	many	data	were	miss‐
ing	for	total	faecal	protein,	only	summary	statistics	were	calculated	
for	this	parameter.
The	study	was	reviewed	and	approved	by	the	institutional	review	
board	or	independent	ethics	committee	at	each	hospital	and	the	par‐
ent	or	legal	representative	of	each	participant	provided	written,	in‐
formed	consent	prior	to	enrolment.	The	Clinical	Trial	Registration	for	
the	study	was	NCT01771588.
3  | RESULTS
The	study	flow	diagram,	baseline	subject	characteristics	and	paren‐
tal	 demographics	 have	previously	 been	 reported.15	A	 total	 of	 153	
infants	 were	 enrolled	 and	 randomised	 to	 either	 the	 new	 fortifier	
(n	=	77)	or	the	control	fortifier	(n	=	76).	One	infant	in	the	new	group	
was	excluded	due	to	a	history	of	systemic	disease,	and	two	in	the	con‐
trol	group	were	small	for	gestational	age,	leaving	76	and	74,	respec‐
tively.	The	infant	characteristics	were	similar	between	the	new	and	
control	groups:	50%	and	53%	of	girls,	32%	and	27%	of	vaginal	births	
and	 24%	 and	 22%	 of	 twins,	 respectively.	 The	 mean	 birthweights	
were	1147	±	258	g	and	1156	±	289	g,	and	the	mean	gestational	ages	
at	birth	were	28.8	±	2.1	weeks	and	28.7	±	1.18	weeks.	As	shown	in	
Figure	1,	only	56%‐94%	of	the	population	provided	data	for	the	stool	
analyses	(depending	on	time	point	and	parameter),	due	to	the	diffi‐
culty	in	obtaining	sufficient	stool	quantities	for	all	subjects.
There	were	no	significant	differences	 in	any	 faecal	biomarkers	
at	FS	day	one	(Figure	2).	The	geometric	mean	concentrations	of	fae‐
cal	alpha‐1	antitrypsin	(Figure	2A)	and	faecal	elastase‐1	(Figure	2C)	
were	 significantly	 lower	 in	 the	 new	 fortifier	 group	 compared	 to	
the	 control	 fortifier	 group	at	 study	day	21	 (P = .010	and	 .016,	 re‐
spectively).	 In	addition,	the	increase	from	FS	day	one	to	study	day	
21	 for	 both	of	 these	parameters	was	 significantly	 less	 in	 the	 new	
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fortifier	group	compared	to	the	control	fortifier	group	(P = .007 and 
.004,	 respectively).	 Faecal	 calprotectin	 concentrations	 (Figure	 2B)	
tended	to	increase	in	both	groups	during	the	study,	according	to	the	
Satterthwaite	 test.	The	P‐values	 associated	with	 the	 test	of	mean	
changes	from	FS	day	one	to	study	day	21	 in	the	new	fortifier	and	
control	fortifier	groups	were	P	=	.051	and	P	=	.112,	respectively,	with	
no	significant	difference	between	groups	demonstrated	at	study	day	
21	or	in	the	adjusted	change	over	time.	The	evaluation	of	the	total	
protein	concentration	in	stools	was	limited	due	to	inadequate	stool	
material	in	89%	of	cases	at	FS	day	one	and	85%	of	cases	on	study	day	
21.	Nevertheless,	no	significant	difference	was	observed	between	
the	groups	on	FS	day	one	when	we	looked	at	the	medians	and	inter‐
quartile	ranges:	these	were	1.70	(1.45‐1.80)	for	the	new	fortifier	vs	
1.40	(1.30‐1.53)	for	the	control	fortifier	(P = .100).	The	values	were	
also	similar	in	both	groups	at	study	day	21,	namely	1.60	(1.50‐1.63)	
for	the	new	fortifier	vs	1.60	(1.50‐1.70)	for	the	control	fortifier.	No	
inferential	statistics	were	performed	at	study	day	21	because	85%	
of	the	values	were	missing.
4  | DISCUSSION
This	report	presents	faecal	biomarkers	of	gastrointestinal	inflamma‐
tion	and	gut	maturity	in	clinically	stable,	preterm	infants	fed	human	
milk	fortified	with	either	a	new	or	control	multinutrient,	powdered	
fortifier.	Our	results	indicate	that	the	different	human	milk	fortifiers	
led	to	limited	differences	in	faecal	biomarkers	of	gastrointestinal	sta‐
tus	in	this	population.
The	faecal	alpha‐1	antitrypsin	results	observed	here	may	have	
been	due	to	several	factors.	First,	alpha‐1	antitrypsin	is	present	in	
human	milk19,20	 and	appears	 to	 increase	with	 lactation.19	Human	
milk	 alpha‐1	 antitrypsin	 is	 also	 resistant	 to	 pasteurisation21 and 
proteolysis	 in	 young	 infants,22	 meaning	 that	 faecal	 concentra‐
tions	may	 be	 high,	 or	 change	 over	 time,	 even	 in	 the	 absence	 of	
enteropathy.	It	is	likely	that	this	accounted	for	the	higher	levels	of	
this	protein	in	the	two	study	groups	when	they	were	compared	to	
infants	who	were	 predominantly	 fed	 preterm	 formula.19,20,23	 For	
example,	 Sivan	 et	 al23	 reported	 concentrations	 of	 faecal	 alpha‐1	
antitrypsin	in	a	sample	of	preterm	infants	who	were	predominantly	
fed	 formula.	These	 ranged	 from	0.34	 to	1.05	mg/g	stools,	which	
was	lower	than	the	geometric	mean	values	observed	in	our	study	
(Figure	2).	However,	it	is	unlikely	that	the	alpha‐1	antitrypsin	con‐
tent	 of	 human	milk	 contributed	 to	 the	 small,	 but	 significant,	 dif‐
ference	 between	 the	 groups	 on	 study	 day	 21,	 since	 each	 group	
consumed	a	very	similar	volume	of	fortified	milk	during	the	study	
period.	This	was	153	mL/kg/d	in	both	groups,	with	49%	of	the	vol‐
ume	 from	 donor	milk	 in	 the	 new	 fortifier	 group	 and	 51%	 in	 the	
control	 fortifier	 group.15	 Alternatively,	 it	 can	 be	 speculated	 that	
these	 results	 indicate	a	 slight,	but	 significant,	 increase	 in	gastro‐
intestinal	protein	 loss	and,	or,	 inflammation	among	 infants	 in	 the	
control	 than	new	 fortifier	 groups.	However,	 the	geometric	mean	
concentrations	 in	 both	 groups	were	 substantially	 lower	 than	 the	
cut‐off	 value	 previously	 associated	 with	 various	 gastrointestinal	
diseases	in	children	(2.6	mg/g	stools)24	and	the	difference	between	
the	groups	was	quite	small	(0.30	mg/g	stools).
In	a	2016	systematic	review,	Pergialiotis	et	al25	concluded	that	
faecal	calprotectin	was	elevated	in	newborns	with	NEC.	However,	
faecal	 calprotectin	has	also	been	 shown	 to	be	higher	 in	healthy,	
exclusively	breastfed	infants	than	in	infants	fed	formula	or	a	mix‐
ture	of	breast	milk	and	formula,26,27	suggesting	that	higher	levels	
F I G U R E  1  Flow	of	study	participants	
and	sample	sizes	for	stool	analyses.	FS	day	
1	=	fortification	strength	day	one.	Day	
21	=	study	day	21
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may	not	always	indicate	pathology.	Consistent	with	this	hypothe‐
sis,	Groer	et	al28	showed	that	infants	who	received	their	mother's	
own	milk	had	increasing	faecal	calprotectin	levels	over	time,	while	
infants	who	received	mixed	feeding	or	pasteurised	donor	milk	did	
not	 show	 this	 increase	over	 time.	Together,	 these	previous	 find‐
ings	 suggest	 that	 faecal	 calprotectin	 may	 not	 always	 represent	
pathological	 inflammation	 in	 preterm	 infants,	 but	 rather	 feed‐
ing	pattern	and,	or,	normal	maturation	of	the	gut	 immune	axis.28 
Furthermore,	 no	 infants	 in	 our	 study	 experienced	 NEC,	 despite	
the	fact	 that	many	had	calprotectin	 levels	 (ie	median	 [Q1‐Q3]	of	
296	[136‐565]	μg/g	stools	 in	both	groups	combined	at	study	day	
21)	that	greatly	exceeded	those	reported	to	be	 indicative	of	this	
condition.25,29	 In	 our	 study,	 the	 slight	 increase	 in	 faecal	 calpro‐
tectin	over	time	in	both	the	fortifier	groups	was	likely	to	have	re‐
flected	both	feeding	with	human	milk	fortifier	plus	mixed	sources	
of	human	milk	and	normal	gastrointestinal	maturation	and	devel‐
opment.	The	 lack	of	a	significant	difference	between	the	groups	
was	consistent	with	a	previous	study	that	showed	no	differences	
in	 this	 biomarker	 prior	 to	 commencing	 fortification	 or	 14	 days	
after	fortification	with	either	a	human	milk	or	bovine	milk‐based	
fortifier.30	 Our	 results	 also	 provide	 further	 evidence	 that	 more	
work	is	needed	to	identify	an	appropriate	diagnostic	cut‐off	value	
for	NEC.	This	finding	was	consistent	with	the	conclusions	reached	
by	Pergialiotis	et	al.25
Reduced	 elastase‐1	 secretion	 in	 stools	 is	 considered	 to	 be	 a	
marker	of	pancreatic	insufficiency,	with	values	of	less	than	200	μg/g	
stools	 indicating	 impaired	 exocrine	 pancreatic	 function.31	 Values	
have	been	shown	to	normalise	 for	most	 infants,	 including	preterm	
infants,	within	the	first	 few	weeks	after	birth.12,32	Preterm	 infants	
have	been	shown	to	exhibit	pancreatic	immaturity	and	high	sensitiv‐
ity	to	environmental	stress,	including	inappropriate	nutrient	uptake	
related	to	defects	in	the	gut	barrier	function.3	Given	that	nutrients	
within	the	duodenal	lumen	are	the	most	important	stimulators	of	the	
pancreatic	exocrine	response,33	it	can	be	hypothesised	that	such	in‐
appropriate	uptake	might	lead	to	excessive	elastase	production	and	
secretion	into	the	gut	 lumen.	Excessive	elastase	activity	 in	the	gut	
lumen	may	contribute	to	maintenance	or	exacerbation	of	inflamma‐
tory	 status,34	 leading	 to	metabolic	 stress	 and	 an	 increased	 risk	of	
feeding	intolerance	and	NEC.35	In	the	present	study,	preterm	infants	
fed	with	the	new	fortifier	presented	with	slightly	lower	levels	of	fae‐
cal	elastase	at	study	day	21	than	the	group	who	received	the	control	
fortifier.	This	finding	suggests	that	the	new	fortifier	may	have	had	a	
modest	impact	on	gut	homeostasis.
To	 our	 knowledge,	 this	 was	 the	 first	 study	 to	 assess	 multiple	
faecal	markers	of	gastrointestinal	inflammation	and	maturity	of	gut	
function	in	response	to	different	forms	of	human	milk	fortification	
in	preterm	infants.	A	limitation	was	that	the	number	of	samples	of	
sufficient	quantity	for	all	analyses	ranged	from	10%	to	85%	of	the	
full	sample	size.
5  | CONCLUSION
These	results	indicate	that	different	human	milk	fortifiers	can	lead	
to	modest	differences	in	markers	of	gastrointestinal	status	in	clini‐
cally	stable,	preterm	 infants.	The	mean	values	of	each	marker	 in	
both	fortifier	groups	were	within	the	ranges	observed	in	healthy	
term	infants.	In	addition,	these	results	suggest	that	the	faecal	cal‐
protectin	 threshold	 value	 for	 early	 detection	 of	 NEC	 should	 be	
revised	 in	 light	of	 the	 relatively	high	concentrations	observed	 in	
our	subjects.	When	they	are	combined	with	previously	 reported	
F I G U R E  2  Geometric	mean	*/÷	geometric	SD	for	faecal	
alpha‐1	antitrypsin	(panel	A),	faecal	calprotectin	(panel	B)	and	
faecal	elastase	(panel	C).	Black	circles/solid	line	represent	new	
fortifier	and	open	squares/dashed	line	represent	control	fortifier.	
FS	day	one	=	fortification	strength	day	one	and	day	21	=	study	
day	21.	*P = .017	vs	FS	day	one	value	(by	t	test	computed	using	
Satterthwaite	method);	†P = .010	vs	control	fortifier	(by	analysis	
of	covariance,	adjusting	for	value	at	FS	day	one,	sex	and	centre);	
‡P = .016	vs	control	fortifier	(by	analysis	of	covariance,	adjusting	for	
value	at	FS	day	one,	sex	and	centre)
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anthropometry	 and	 clinical	 biochemistry	 data,	 these	 results	 fur‐
ther	 illustrate	 that	 the	new	 fortifier	was	 safe	 and	well	 tolerated	
by	our	cohort.
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